Dose Finding Safety Study of VAL201 in Cancer Patients

The study will enrol patients with locally advanced or metastatic prostate cancer. The MTD/MAD may also be evaluated in patients with other advanced tumour types for whom no standard effective therapy is available and a rationale for use of VAL201 exists.

The average timeframe is 18-26 weeks per subject and the outcome measured is a composite average for each group.

• Inclusion criteria:
• Specific Inclusion Criteria for Patients with Prostate Cancer
• Patients with incurable, locally advanced or metastatic prostate cancer where a policy of intermittent hormone therapy has been decided. Who have specific clinical parameters.
• Specific Inclusion Criteria for Patients with Other Advanced Solid Tumours
• Patients with histologically and/or cytologically confirmed advanced solid tumour for whom no standard effective therapy is available and a rationale for use of VAL201 exists.
• Patients with incurable, locally advanced or metastatic prostate cancer where a policy of intermittent hormone therapy has been decided. These patients must also have the following:
• Rising PSA on three samples (once non-castrate levels established); each over 2 weeks apart, with the last two values being greater than 2 ng/mL. Higher than and at least 25% over the nadir.
• Absent or very mild prostate cancer-related symptoms.
• No plans for any therapy for prostate cancer in the next two months.
• General Inclusion Criteria for all Patients
• Adult patients defined by age greater than 18 years at time of consent.
• Ability to give written, informed consent prior to any study-specific Screening procedures, with the understanding that the consent may be withdrawn by the patient at any time without prejudice.
• Patient is capable of understanding the protocol requirements, is willing and able to comply with the study protocol procedures, and has signed the informed consent document.
• Evaluable disease, either measurable on imaging, or with informative tumour marker(s) and a set of specific biochemical and haematological parameters relating to the specific cancer.
• Negative human chorionic gonadotropin (hCG) test in women of childbearing potential.
• Sexually active male and female patients of childbearing potential must agree to use an effective method of birth control. Female patients may be surgically sterile.
• Laboratory values at Screening:
• Absolute neutrophil count ≥1.5 x 109/L.
• Platelets ≥100 x 109/L.
• Haemoglobin ≥9 g/dL without blood transfusion or colony stimulating factor support.
• Total bilirubin 50 mL/min based on the Cockcroft-Gault formula.
• Exclusion criteria
• Specific Exclusion Criteria for Patients with Prostate Cancer Patients has received an anticancer therapy, including investigational agents, within the precious 6 weeks or 4 weeks.
• Any patients who have undergone prior orchidectomy.
• Specific Exclusion Criteria for Patients with Other Advanced Solid Tumours Pregnant or lactating female patients.
• Documented, symptomatic or uncontrolled brain metastases.
• History of clinically significant cardiac condition, including ischemic cardiac event, myocardial infarction or unstable cardiac disease within 3 months previous to the indication of home therapy.
• Known Human Immunodeficiency Virus positivity.
• Active Hepatitis B or C or other active liver disease (other than malignancy).
• Any active, clinically significant, viral, bacterial, or systemic fungal infection within previous 4 weeks prior to home therapy.
• Any medical history that would jeopardize compliance.